11 stories mentioning ARWRUpdated 9d ago
Every FINWIRES story that references ARWR, newest first.
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $105.40, according to analysts polled by FactSet.Price: $87.58, Change: $+1.36, Percent Change: +1.58%
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at about $1.5 billion, the companies said. Repligen shares climbed 2.3%, and BioLife jumped past 6%.Amgen (AMGN) has agreed to pay $74 million to settle a shareholder lawsuit alleging the company waited too long to disclose it may owe the Internal Revenue Service $10.7 billion in back taxes, penalties and interest, news outlets reported Tuesday. Amgen shares were down 0.1%.Arrowhead Pharmaceuticals (ARWR) shares surged past 20% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.GSK (GSK) shares were fractionally higher after it said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Arrowhead Pharmaceuticals (ARWR) shares jumped past 21% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.
Arrowhead Pharmaceuticals (ARWR) shares rose 22.1% on Wednesday after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.Studies also met all secondary endpoints, including a statistically significant reduction in the rate of acute pancreatitis compared with placebo, according to a statement.The 25 mg dosage administered subcutaneously once every three months led to median triglyceride reductions of 79% and 81%, respectively, at month 12, the company said.The drug candidate demonstrated a favorable safety and tolerability profile, with treatment emergent adverse events consistent with its established safety profile, the company said.The company will utilize phase 3 trial data to apply for marketing authorization for sHTG in multiple global geographies, beginning with a planned supplemental new drug application with the US FDA before 2026-end, according to the company.Price: $90.87, Change: $+16.35, Percent Change: +21.94%
Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical studies of plozasiran in patients with severe hypertriglyceridemia showed the trials "successfully met" primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints in both studies.Shares surged 24% amid an increase in intraday trading volume to over 4.8 million from a daily average of roughly 2.1 million.Super Micro Computer (SMCI) soared 22% amid heavy trading after the company said it expects fiscal Q4 GAAP and non-GAAP gross margins in the range of 15% to 17%, significantly above its 8.2% to 8.4% forecast on the back of a favorable customer and product mix, according to a statement late Tuesday.Over 126 million shares traded intraday versus a daily average of roughly 51.4 million.First Financial Bancorp (FFBC) agreed to acquire Finward Bancorp (FNWD) for about $208 million in stock to expand in northwest Indiana and Chicago, according to a statement late Tuesday.Shares jumped 22%, with intraday trading volume rising to more than 126,900 from the stock's daily average of about 17,000.Price: $31.31, Change: $+5.81, Percent Change: +22.79%
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $91.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Arrowhead Pharmaceuticals (ARWR) said Monday the European Commission has granted marketing authorization for Redemplo as an adjunct to diet to reduce triglyceride levels in adults with familial chylomicronemia syndrome.The approval was supported by positive phase 3 Palisade trial data, the company said.Shares were up over 1% in afternoon trading.Price: $82.98, Change: $+1.16, Percent Change: +1.42%
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.Price: $73.94, Change: $-4.01, Percent Change: -5.14%
Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.Price: $76.58, Change: $+0.19, Percent Change: +0.25%
Arrowhead Pharmaceuticals (ARWR) has an average rating of buy and mean price target of $85.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Arrowhead Pharmaceuticals (ARWR) has an average rating of Buy and mean price target of $84.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
